Canadian journal of ophthalmology. Journal canadien d'ophtalmologie最新文献

{"title":"Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis.","authors":"Alaa Tayyib, Deepika C Parameswarappa, Peter J Kertes, Rajeev Muni, Anupreet Tumber, Gregory Costain, Alex Schramm, Heather MacDonald, Regan Klatt, Ajoy Vincent, Elise Héon","doi":"10.1016/j.jcjo.2024.12.006","DOIUrl":"10.1016/j.jcjo.2024.12.006","url":null,"abstract":"<p><strong>Objective: </strong>Assess safety and effectiveness of subretinal gene replacement therapy at 18 months post treatment.</p><p><strong>Design: </strong>Retrospective, longitudinal study conducted at the Hospital for Sick Children in Toronto, Canada.</p><p><strong>Participants: </strong>Patients with bi-allelic RPE65 variants, early onset retinal degeneration, and residual viable retina who underwent voretigene neparvovec r-zyl gene replacement therapy.</p><p><strong>Methods: </strong>Data collected included demographic information, molecular genetic results, and comprehensive ocular assessment results from preoperataive and postoperative visits up to 18 months. To assess the treatment's efficacy, postoperative best corrected visual acuity, full-field stimulus test (FST), visual field (VF) area, optical coherence tomography, and global satisfaction were compared to preoperative findings.</p><p><strong>Results: </strong>The procedures were safe with no complications. There was no significant improvement in visual acuity. Three eyes showed a slight reduction in VF area. All showed a reduction in ellipsoid zone thickness and area, but the outer nuclear layer thickness and area were stable. All had a significant improvement in retinal sensitivity, as per FST, allowing better navigation in a dim environment. All 3 patients reported being \"very satisfied\".</p><p><strong>Conclusion: </strong>Following a safe gene replacement therapy, the 3 first Canadian cases had an improvement in retinal sensitivity as per FST, and our patients described their experience as positively life changing.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the performance of Microsoft Copilot, GPT-4 and Google Gemini in ophthalmology.","authors":"Meziane Silhadi, Wissam B Nassrallah, David Mikhail, Daniel Milad, Mona Harissi-Dagher","doi":"10.1016/j.jcjo.2025.01.001","DOIUrl":"10.1016/j.jcjo.2025.01.001","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the performance of large language models (LLMs), specifically Microsoft Copilot, GPT-4 (GPT-4o and GPT-4o mini), and Google Gemini (Gemini and Gemini Advanced), in answering ophthalmological questions and assessing the impact of prompting techniques on their accuracy.</p><p><strong>Design: </strong>Prospective qualitative study.</p><p><strong>Participants: </strong>Microsoft Copilot, GPT-4 (GPT-4o and GPT-4o mini), and Google Gemini (Gemini and Gemini Advanced).</p><p><strong>Methods: </strong>A total of 300 ophthalmological questions from StatPearls were tested, covering a range of subspecialties and image-based tasks. Each question was evaluated using 2 prompting techniques: zero-shot forced prompting (prompt 1) and combined role-based and zero-shot plan-and-solve+ prompting (prompt 2).</p><p><strong>Results: </strong>With zero-shot forced prompting, GPT-4o demonstrated significantly superior overall performance, correctly answering 72.3% of questions and outperforming all other models, including Copilot (53.7%), GPT-4o mini (62.0%), Gemini (54.3%), and Gemini Advanced (62.0%) (p < 0.0001). Both Copilot and GPT-4o showed notable improvements with Prompt 2 over Prompt 1, elevating Copilot's accuracy from the lowest (53.7%) to the second highest (72.3%) among the evaluated LLMs.</p><p><strong>Conclusions: </strong>While newer iterations of LLMs, such as GPT-4o and Gemini Advanced, outperformed their less advanced counterparts (GPT-4o mini and Gemini), this study emphasizes the need for caution in clinical applications of these models. The choice of prompting techniques significantly influences performance, highlighting the necessity for further research to refine LLMs capabilities, particularly in visual data interpretation, to ensure their safe integration into medical practice.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complication rates in cataract surgery before and during the COVID-19 pandemic.","authors":"Lee-Wing Nathan, Stockl Frank, Wiens James","doi":"10.1016/j.jcjo.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.jcjo.2024.12.001","url":null,"abstract":"<p><strong>Objective: </strong>To assess the cataract surgery (CS) complication rates before and during the COVID-19 pandemic.</p><p><strong>Design: </strong>Retrospective, cross sectional study.</p><p><strong>Methods: </strong>Medical records of patients undergoing CS at two surgery centers in Winnipeg from January 2018 to April 2022 were reviewed. The study periods were pre-COVID-19 (January 1, 2018 to March 31, 2020) and COVID-19 (April 1, 2020 to April 30, 2022). Complication rates for endophthalmitis, sulcus-positioned intraocular lens (IOL) implant, anterior chamber IOL (ACIOL) implant, capsular tension ring (CTR) insertion, cumulative dissipated phacoemulsification energy (CDE), posterior capsular rupture (PCR), unplanned anterior vitrectomy, and return to the OR within one month of surgery were compared.</p><p><strong>Results: </strong>45,559 patients were included. Pre-COVID-19 rates were compared to COVID-19 rates and stated as per 100 cataract surgeries. Endophthalmitis rates increased from 0.008 to 0.028 (RR 0.27, p=0.09). Sulcus IOL implant rates increased from 0.61 to 1.00 (RR 0.61, p<0.0001). ACIOL implant rates increased from 0.53 to 0.68 (RR 0.78, p=0.05). CTR usage rates increased from 0.48 to 0.75 (RR 0.63, p=0.001). Average CDE increased from 4.6 to 6.7 (p=0.0030). PCR rates decreased from 0.49 to 0.38 (RR 1.3, p=0.14). Unplanned anterior vitrectomy rates decreased from 0.43 to 0.36 (RR 1.18, p=0.35). Return to OR rates remained unchanged at 0.59 and 0.58 (RR 1.01, p=0.93).</p><p><strong>Conclusions: </strong>Our study found significant increases in some CS complication rates when comparing the defined pre-COVID interval to the COVID interval.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exudative subretinal fluid associated with tebentafusp immunotherapy","authors":"Joana Andoh,&nbsp;Loka Thangamathesvaran,&nbsp;J. Fernando Arevalo","doi":"10.1016/j.jcjo.2024.08.003","DOIUrl":"10.1016/j.jcjo.2024.08.003","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e170-e173"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and characterization of intraocular foreign body injuries from a Canadian centre: a 20-year retrospective study and literature review","authors":"Abdullah Al-Ani ,&nbsp;Mohamed S Bondok ,&nbsp;Kian Madjedi ,&nbsp;Shellina Kherani ,&nbsp;Amin Kherani","doi":"10.1016/j.jcjo.2024.05.019","DOIUrl":"10.1016/j.jcjo.2024.05.019","url":null,"abstract":"<div><h3>Objectif</h3><div>Analyser l’évaluation et la prise en charge des corps étrangers intraoculaires (CEIO) en milieu urbain au Canada pour générer une perspective clinique précieuse afin de replacer la prise en charge dans son contexte.</div></div><div><h3>Méthodes</h3><div>Examen rétrospectif des dossiers médicaux des patients d'un seul chirurgien datés de janvier 2002 à janvier 2023 comprenant les caractéristiques démographiques de patients qui ont eu un CEIO, leurs examens, leurs traitements, leurs complications et leur meilleure acuité visuelle corrigée (MAVC).</div></div><div><h3>Résultats</h3><div>Notre étude a porté sur la présence d'un CEIO dans 32 yeux de 31 patients (96,8 % des patients étaient de sexe masculin). La taille du CEIO variait de 1 à 12 mm; 28 corps étrangers (87,5 %) étaient en métal; il s'agissait d'un accident de travail dans 15 cas (46,9 %). Dans le cadre de l'examen diagnostique, 19 patients (61,3 %) ont fait l'objet d'une tomographie assistée par ordinateur (TAO), et 8 patients (25,8 %), d'une échographie oculaire (B-scan). La TAO a permis de déceler les CEIO dans 100 % des cas, et les B-scans, dans 87,5 % des cas. Lors du suivi final, la MAVC de 17 yeux (53,1 %) était ≥ 20/40, comparativement à 7 yeux (23,3 %) au départ. Une MAVC ≥ 20/200 lors de l'examen initial était associée à une MAVC finale ≥ 20/40 (<em>p</em> = 0,027). Le CEIO a pu être retiré dans 27 yeux (84,4 %), est demeuré en place dans 4 yeux (12,5 %) et a entraîné l’énucléation de 1 œil (3,1 %). Des antibiotiques ont été administrés par voie intravitréenne dans 19 yeux (59,4 %), ce qui a donné lieu à 1 cas présumé de toxicité médicamenteuse. Des complications sont survenues dans 30 yeux (93,8 %) pour un total de 119, dont 72 (60,5 %) sont apparues pendant les 24 premières heures. La cataracte post-traumatique était la complication la plus fréquente (27 yeux; 84,4 %). Les complications moins fréquentes comprenaient la sidérose oculaire et le décollement de la rétine s'accompagnant d'une vitréorétinopathie proliférante (chacune ayant touché 1 œil; 3,1 %). Enfin, un glaucome secondaire est apparu dans 4 yeux (12,5 %), dont 3 où le CEIO était demeuré en place ou avait été extrait tardivement.</div></div><div><h3>Conclusions</h3><div>Les caractéristiques des CEIO et les paramètres démographiques des patients cadrent avec ceux d'autres régions. La TAO était l'outil d'examen le plus efficace. On recommande un suivi prolongé pour surveiller les complications, surtout en cas de rétention du CEIO ou lorsque son extraction est significativement retardée.</div></div>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e83-e91"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of eye care and health among Indigenous Peoples in Canada","authors":"Justin Kritzinger ,&nbsp;Yuri V. Chaban ,&nbsp;Myrna Lichter ,&nbsp;Helen Dimaras","doi":"10.1016/j.jcjo.2024.07.002","DOIUrl":"10.1016/j.jcjo.2024.07.002","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Many Indigenous Peoples are at risk of poor eye health outcomes due to the various financial, social, geographic, and cultural barriers faced when accessing care. Available literature indicates Indigenous populations across Canada suffer greater rates of eye diseases, including diabetic retinopathy, uveitis, and untreated refractive error, as well as their associated complications. However, many gaps within the current state of knowledge exist. Here, we review the available literature regarding the prevalence of eye disease among Indigenous populations in Canada, as well as previously trialed models of eye care delivery. Various models have been attempted to increase access to eye care for Indigenous communities, although several are focused on screening for diabetic retinopathy in northern populations, with many Indigenous Peoples remaining at risk for poor eye health and permanent vision loss. Failing to address the eye care needs of Indigenous communities will hinder the development of adequate solutions, leading to profound inequities, poor eye health outcomes, and greater vision loss among this population. Future research should seek to understand the root causes of why Indigenous communities have high rates of diabetes and associated ocular complications, including the roles of discrimination, colonialism, and mistrust toward the health care system.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;La santé oculaire de bon nombre d'Autochtones risque d’être médiocre en raison des différents obstacles – qu'ils soient économiques, sociaux, géographiques ou culturels – auxquels ils font face pour accéder à des soins. Selon les articles publiés à ce jour, les peuples autochtones de l'ensemble du Canada sont affligés d'un taux de maladies oculaires plus élevé, notamment la rétinopathie diabétique, l'uvéite et les erreurs de réfraction non corrigées, sans compter les complications qui s'y greffent. Cela dit, nos connaissances actuelles sur la question sont loin d’être complètes. Nous avons donc entrepris de passer en revue la littérature existante sur la prévalence des maladies oculaires au sein des populations autochtones au Canada et d'examiner les modèles de prestation des soins oculaires qui ont déjà été mis à l'essai. En effet, différents modèles d'amélioration de l'accès aux soins oculaires ont été testés auprès des communautés autochtones. Comme plusieurs modèles mettent surtout l'accent sur le dépistage de la rétinopathie diabétique dans les populations nordiques, un grand nombre d'Autochtones continuent d’être exposés à un risque de santé oculaire médiocre et de perte de vision permanente. En n'abordant pas les besoins des communautés autochtones en matière de prestation des soins oculaires, on nuit à la création de solutions adéquates, ce qui se traduit par l'apparition d'inégalités criantes, d'une santé oculaire médiocre et d'une perte de vision plus importante au sein de ces populations. Les études futures doivent se pencher sur les causes profondes à l","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages 1-7"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative grading of vitreous inflammation using two wide field fundus retinographs","authors":"Yoo-Ri Chung ,&nbsp;Alessandro Falcione ,&nbsp;Bayram Mhibik ,&nbsp;Bahram Bodaghi ,&nbsp;Sara Touhami","doi":"10.1016/j.jcjo.2024.07.022","DOIUrl":"10.1016/j.jcjo.2024.07.022","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e152-e153"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentre analysis of nucleic acid quantification using aqueous humour liquid biopsy in uveal melanoma: implications for clinical testing","authors":"Sarah B. Pike ,&nbsp;Mark W Reid ,&nbsp;Chen-Ching Peng ,&nbsp;Christina Chang ,&nbsp;Benjamin Y. Xu ,&nbsp;Dan S. Gombos ,&nbsp;Sapna Patel ,&nbsp;Liya Xu ,&nbsp;Jesse L. Berry","doi":"10.1016/j.jcjo.2023.10.024","DOIUrl":"10.1016/j.jcjo.2023.10.024","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Uveal melanoma&lt;span&gt;&lt;span&gt; (UM) tumour biopsy is limited by size and intratumour heterogeneity. We explored the potential of &lt;/span&gt;aqueous humour (AH) &lt;/span&gt;&lt;/span&gt;liquid biopsy&lt;span&gt; for UM by quantifying analytes in samples collected at diagnosis and after brachytherapy to look for clinical correlations with tumour features.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Case-series study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Sixty-six UM patients and 16 control subjects from a tertiary care hospital.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;span&gt;&lt;span&gt;The study included 119 UM AH samples and 16 control samples analyzed for unprocessed analytes (i.e., dsDNA, &lt;/span&gt;miRNA, and protein) using &lt;/span&gt;Qubit&lt;span&gt; fluorescence assays.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Analytes were widely quantifiable among available UM AH samples (dsDNA: 94.1%; miRNA: 88.0%; protein: 95.2%) at significantly higher concentrations than among control samples (dsDNA, &lt;/span&gt;&lt;em&gt;p&lt;/em&gt;&lt;span&gt; = 0.008; miRNA, &lt;/span&gt;&lt;em&gt;p&lt;/em&gt; &lt; 0.0001; protein, &lt;em&gt;p&lt;/em&gt;&lt;span&gt;&lt;span&gt; = 0.007). In samples taken at diagnosis, concentrations were higher at more advanced American Joint Cancer Commission stages; when comparing most advanced stage III with least advanced stage I, median &lt;/span&gt;dsDNA was 4 times greater (&lt;/span&gt;&lt;em&gt;p&lt;/em&gt; &lt; 0.0001), miRNA was 2 times greater (&lt;em&gt;p&lt;/em&gt; = 0.001), and protein was 3 times greater (&lt;em&gt;p&lt;/em&gt; &lt; 0.0001). Analytes were quantifiable in &gt;70% of diagnostic samples from eyes with tumours &lt;2 mm tall. Height had a positive association with diagnostic analyte concentrations (dsDNA: &lt;em&gt;R&lt;/em&gt; = 0.43, &lt;em&gt;p&lt;/em&gt; = 0.0007; miRNA: &lt;em&gt;R&lt;/em&gt; = 0.35, &lt;em&gt;p&lt;/em&gt; = 0.01; protein: &lt;em&gt;R&lt;/em&gt; = 0.39, &lt;em&gt;p&lt;/em&gt; = 0.005). Samples taken after brachytherapy showed significantly higher concentrations than diagnostic samples (&lt;em&gt;p&lt;/em&gt; &lt; 0.01 for all).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;UM AH is a rich repository of analytes. Samples from eyes with more advanced stage and larger tumours had higher concentrations, though analytes also were quantifiable in eyes with smaller, less advanced tumours. Future analysis of AH analytes may be informative in the pursuit of personalized UM treatments.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;En présence d'un mélanome de l'uvée (MU), la biopsie de la tumeur est limitée par sa taille et par l'hétérogénéité intratumorale. Nous avons examiné l'intérêt de la biopsie liquide de l'humeur aqueuse (HA) dans le MU en quantifiant les analytes dans les échantillons recueillis au moment du diagnostic et après la curiethérapie afin de faire ressortir des corrélations cliniques en lien avec les caractéristiques de la tumeur.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Nature&lt;/h3&gt;&lt;div&gt;Série de cas.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;L’étude portait sur 66 patients présentant un MU et 16 sujets témoins provenant d'un hôpital de soins tertiaires.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;L’étude co","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e23-e31"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reperfusion of macular vasculature in lupus-mediated occlusive vasculopathy","authors":"Peter J. Weng,&nbsp;Dilraj S. Grewal","doi":"10.1016/j.jcjo.2024.07.016","DOIUrl":"10.1016/j.jcjo.2024.07.016","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Page e162"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant","authors":"Bryan G. Pearson ,&nbsp;Ray S. Cortez ,&nbsp;Karima S. Khimani ,&nbsp;Praveena K. Gupta","doi":"10.1016/j.jcjo.2024.04.005","DOIUrl":"10.1016/j.jcjo.2024.04.005","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;This study investigates ocular manifestations of graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation (HSCT) at the University of Texas Medical Branch (UTMB). Preferred practice pattern guidelines are proposed for ocular graft-versus-host disease (oGHVD) detection.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;span&gt;The Epic electronic medical record database at UTMB was screened using &lt;/span&gt;&lt;em&gt;International Classification of Diseases&lt;/em&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;, Tenth Revision (ICD-10), codes for bone marrow transplants, &lt;/span&gt;stem cell transplants, and complications of bone marrow transplants and stem cell transplants. We identified 50 patients with the ICD-10 codes that were seen at UTMB between 2000 and 2021. Patients who received an &lt;/span&gt;HSCT and follow-up care with UTMB were included in this study. Thirty-eight patients met the inclusion criteria, whereas 12 patients were excluded because they had no diagnosis of HSCT or did not follow-up with UTMB.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Of the 38 patients in our cohort, 23.7% (n = 9) were noted to have oGVHD. As many as 89% of the patients with oGVHD presented with an ocular surface disease including &lt;/span&gt;keratoconjunctivitis sicca&lt;span&gt;, meibomian gland dysfunction&lt;span&gt;, and dry eye syndrome. Systemic GVHD also was found in 44% of the patients with oGVHD. Only 29% (n = 11) of the study population had referrals to ophthalmology. Most referrals (55%) were made within 1 year of getting the HSCT. None of the patients in our cohort received an ocular screening before HSCT.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Many post-HSCT patients lack routine ophthalmic&lt;span&gt; care. Regularly assessing post-HSCT patients for early signs and symptoms of oGVHD may limit adverse outcomes. Management of oGVHD should involve a multidisciplinary team approach.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;La présente étude se penche sur les manifestations oculaires de la maladie du greffon contre l'hôte (MGCH) chez des patients qui ont reçu une allogreffe de cellules souches hématopoïétiques (ACSH) à la faculté de médecine de l'Université du Texas (UTMB, pour University of Texas Medical Branch). On y propose des lignes directrices en matière de pratiques courantes privilégiées (&lt;em&gt;Preferred Practice Pattern® Guidelines&lt;/em&gt; de l'AAO) en vue du dépistage de la MGCH oculaire.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;On a extrait les codes correspondant aux greffes de moelle osseuse et aux greffes de cellules souches de même qu’à leurs complications selon la classification internationale des maladies (CIM-10) dans la base de données des dossiers médicaux électroniques Epic de l'UTMB. On a ainsi recensé 50 patients auxquels on a attribué ces codes à l'UTMB entre 2000 et 2021. Seuls les patients qui ont reçu une ACSH à l'UTMB et qui y ont été suivis ont été inclus dans notre étude : 38 patients répondaient aux critères d'inclu","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 1","pages":"Pages e11-e15"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141145696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}